mAbs Agency Consulting firm Experts Specialists Consultancy

Seize opportunities in the monoclonal antibody market

The Alcimed team supports its clients in exploring the development potential of mAbs across different therapeutic indications, monitoring innovation developments to ensure monoclonal antibodies can be used safely and effectively, with improved delivery options for a larger range of patients, from chronic diseases to the use of bispecific antibodies for tumor targeting. The recent success of COVID mAbs in preventing and resolving severe disease highlights the utility of mAbs for combating infectious disease, especially in the immune-compromised and in the context of a global pandemic.

    Tell us about your uncharted territory

    You have a project and want to discuss it with our explorers, write us!

    One of our explorers will contact you shortly.

    They trust us


    The challenges related to mAbs (monoclonal antibodies)

    Monoclonal antibody usage in therapeutics is not new. The first therapeutic use of a mAb was granted approval in 1986 for kidney transplant rejection using an anti-CD3 antibody that was developed in a mouse. Because of its mouse origin, it caused side effects through the development of anti-mouse antibodies, which dramatically decreased the safety of the therapy. Since then mAbs are humanized to prevent this and there are more than 61 monoclonal antibody therapies on the market today. The number of monoclonal antibody therapies is likely to continue growing rapidly.

    The main challenges for the mAb market are:

      Tell us about your uncharted territory

      You have a project and want to discuss it with our explorers, write us!

      One of our explorers will contact you shortly.

      How we support you in your projects related to mAbs (monoclonal antibodies)

      Alcimed supports its clients in understanding the mAbs market in order to better understand the technical and safety challenges surrounding the technology and in the development of new monoclonal antibodies that meet the specific requirements of actors across a wide variety of therapeutic areas from infectious disease to oncology with cancer treatments.

      We thus support decision-makers in the healthcare industry (executive committees, new product strategy, marketing, technology innovation, R&D, …) on exploring this market and in their mAB projects. We are well prepared to help our clients in pharma and biotech, both well-established and emerging, exploring this promising field, such as Eli Lilly, GSK, J&J, Roche, and Merck, just to name a few.

      The wide variety of our clients (pharma players, biotechs, research centers, startups,…), from around the world, and of the types of projects we carry out, gives us a global and in-depth understanding of the changing dynamics in this rapidly growing field of monoclonal antibodies. When combined with our extensive expertise in infectious and chronic disease, and oncology, Alcimed can provide a comprehensive strategic outlook on just how ubiquitously mAbs can be leveraged as a therapeutic approach.

      Examples of recent projects carried out for our clients in mAbs

      • Analyzing the receptivity of mAbs for the treatment of dermatological indications

        Alcimed worked with a major pharma player to understand the potential receptivity of using life-extended monoclonal antibodies to manipulate the commensal bacteria found in the skin to prevent dermatological inflammation.

        Alcimed analyzed the current treatment landscape, the unmet needs in the current standard of care, the lack of innovation in the space, and the receptivity to novel treatment strategies. Using this analysis, Alcimed was able to estimate the potential market sizes for both prophylactic and therapeutic indications across several geographies.

        Our client could then select the right therapeutic target to add to their R&D pipeline for further exploration of the approach’s technical feasibility.

      • State of the art around anti-drug antibodies (ADAs) to determine the development strategy of mAbs in chronic diseases in animals

        Alcimed worked with a major biotech player to conduct an in-depth analysis of the scientific publications related to ADAs for chronic diseases (particularly inflammatory diseases like osteoarthritis or rheumatoid arthritis) to characterize ADAs (etiology, formation mechanism,…) and assess their impacts on the efficacy of a mAb treatment in human and animal health.

        Alcimed also identified the solutions to overcome those impacts either after treatment injection or at an early development stage and assessed the perception of ADAs by the scientific community and health authorities.

        That understanding and analysis of the better ways to circumvent the potential hurdles associated to ADAs, from a scientific and regulatory prospective, allowed to inform on our client’s development strategy for a veterinary mAb.

      • Innovative packaging solutions for mAbs to be used in a go to market strategy

        As seen before, one current limitation of mAbs is their delivery mode, that can restrict their access. One of our clients, a large biotech player, was developing a new Mab, from formulation to packaging.

        On top of scientific and medical considerations, our client wanted to improve the patient and HCP experience with the product itself, during administration notably. We then mapped and characterized the current market standards for secondary packing on high-value injectables including mAbs.

        The reception of such secondary packaging from both healthcare providers and patients was assessed to make critical packaging design decisions for a new product for the treatment of moderate-to-severe atopic dermatitis nearing market launch.

      • Assessing and prioritizing new oral delivery technologies for mAbs

        Alcimed supported a major pharma player in creating a landscape of the most relevant players with technology platforms for oral delivery of mAbs and prioritized them based on development stage and technology platform.

        Based on this landscape Alcimed also defined the strategic value arguments for utilizing oral delivery technologies for mAbs and assembled an expert advisory panel to aid in the adoption of such a strategy.

        We could then select the right partners to move forward with, and refine our client’s strategy based on how favorable the environment is for the use of oral delivery for mAbs.

      You have a project?

        Tell us about your uncharted territory

        You have a project and want to discuss it with our explorers, write us!

        One of our explorers will contact you shortly.

        To go further